Granules India’s US packaging facility clears FDA inspection with zero observations
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
The audit was completed with zero critical and zero major observations
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
The said inspection concluded with Zero Form 483 observation
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
Subscribe To Our Newsletter & Stay Updated